Akita Biosciences is a biotech organization pioneering novel intranasal therapies that help people live healthy and vibrant lives. Akita’s lead product is a once-daily nasal spray that is taken proactively to help reduce the risk of common respiratory infections such as Influenza A, Influenza B, SARS-CoV-2, RSV, Adenovirus, E. coli, and K. Pneumonia. Our proprietary drug delivery platform creates a barrier that controls mucosal absorption and optimizes the residence time across a wide range of molecules and biologics.
Company Details
- Employees
- 8
- Founded
- -
- Address
- Columbus, Ohio, Us
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://www.akitabiosciences.com
- Keywords
- in brand growth.
- HQ
- Columbus, Ohio
Akita Biosciences Questions
Akita Biosciences's website is https://www.akitabiosciences.com
Akita Biosciences's LinkedIn profile is https://www.linkedin.com/company/akita-biosciences
Akita Biosciences has
8 employees.
View email and phone details for 8
employees at Akita Biosciences.
Akita Biosciences's industry is
Biotechnology Research
Akita Biosciences's top competitors are
Fourier Health,
Kisbee Therapeutics,
Verve Therapeutics,
Entrada Therapeutics,
Landmark Bio,
Landsdowne Labs,
Despierta,
Kojin Therapeutics,
Droplet Biosciences, Inc,
Corner Therapeutics.
Akita Biosciences's categories are Biotechnology Research
Akita Biosciences's founding year is 2022
